Key Points for Decision Makers {#FPar1}
==============================

Hepatic encephalopathy (HE) is associated with substantial healthcare utilization (e.g. hospitalizations), which rifaximin has been shown to reduce (e.g. reduction in risk of overt HE recurrence, reduction in overt HE-related hospitalizations).The economic burden of HE on healthcare systems, including annual hospitalizations for patients with overt HE, may be mitigated by rifaximin.The cost savings and clinical benefits of rifaximin in patients with cirrhosis have the potential to benefit healthcare decision making regarding management of HE.

Introduction {#Sec1}
============

Hepatic encephalopathy (HE) is a common neurologic complication of cirrhosis \[[@CR1]\] and is estimated to affect between 30 and 70% of patients with cirrhosis \[[@CR2], [@CR3]\]. Cognitive impairment experienced by patients with HE ranges from minimal (covert) HE, which is detected using specialized testing, to overt HE, which is characterized by clinically identifiable symptoms (e.g. confusion, personality and behavioural changes, lethargy) \[[@CR1], [@CR4]\]. HE negatively impacts multiple aspects of the lives of patients (e.g. cognition, employment, finances) \[[@CR5], [@CR6]\] and their caregivers (e.g. personal health, finances, daily life) \[[@CR6]\]. HE adversely affects sleep quality and sleep efficiency (i.e. time spent sleeping while in bed) \[[@CR7]\] and is associated with learning impairment, which may persist even when overt HE symptoms clinically resolve \[[@CR8], [@CR9]\]. Both general (e.g. physical functioning, social functioning) and disease-specific (e.g. disease effects, memory) health-related quality-of-life (HRQOL) indicators are aberrantly affected in patients with HE compared with patients without the condition \[[@CR10], [@CR11]\]. In one study, 100% of patients with overt HE reported depressive symptoms in the previous 2 weeks, a finding that had a significant negative association with all domains of the general and disease-specific HRQOL instruments used to assess patient functioning (*p *= 0.03 to *p *\< 0.001) \[[@CR10]\].

Patients with a history of HE are at increased risk for HE recurrence; one study estimated that risk of recurrence increased by 23% with every unit increase in the number of prior overt HE episodes (hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.19--1.29) \[[@CR12]\]. It is not uncommon for patients with overt HE to require hospitalization to manage the condition \[[@CR13]--[@CR15]\]; indeed, in a prospective study of patients with cirrhosis, overt HE was the most common cause of patients' initial liver disease-related hospitalizations \[[@CR15]\]. Further, HE was predictive of cirrhosis-related rehospitalization (odds ratio (OR) 5.5; 95% CI 2.0--15.3; *p *= 0.001) \[[@CR16]\]. A study of patients with cirrhosis in a US hospital system reported that overt HE was the most common cause for rehospitalization in community hospitals compared with tertiary-care hospitals (29.5 vs. 8.6%, respectively) \[[@CR17]\]. Furthermore, post-index mean annual hospital costs (2010--2013) for patients with an index hospitalization for complications of cirrhosis, such as HE, were greater for patients rehospitalized ≤ 30 or \> 30 days than for patients who were not readmitted and had outpatient costs only (\$US73,252 and 62,053 vs. 5719, respectively) \[[@CR17]\]. Based on findings of two independent studies conducted in the USA and Canada, an estimated 18.1% of patients with cirrhosis who had been hospitalized previously had an HE-related rehospitalization within 30 days, and an estimated 23.7--28.8% of patients reported an HE-related readmission within 3 months \[[@CR18], [@CR19]\]. A study of patients with HE-related hospitalizations observed that 38.4% were readmitted within 30 days, and an additional 13.6% re-entered the hospital within 31--90 days of their last stay \[[@CR20]\]. An Italian study estimated that 42.5% of patients with a previous overt HE-related hospitalization experienced another such rehospitalization within 1 year \[[@CR21]\]. Another Italian study of patients previously hospitalized for liver disease estimated that this population experienced a mean of 1.5 HE-related readmissions annually during the 3-year period from 2006 through 2008 \[[@CR13]\].

Given the substantial healthcare utilization associated with HE, the aim of this systematic review is to provide an overview of the global costs associated with HE and of management options that have the potential to decrease healthcare utilization in a manner that may be beneficial to patients and healthcare institutions.

Methods {#Sec2}
=======

Reference Search {#Sec3}
----------------

A PubMed search of English language articles available from 1 January 2007 through 23 June 2017 was conducted using the following keywords to identify articles for inclusion in the review: hepatic encephalopathy, economic, health-related quality of life, cost, cost utility, cost effectiveness, rifaximin, lactulose, adherence, and patient-reported outcomes. Abstracts presented at annual meetings of the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and Digestive Disease Week, between 2014 and 2017 (if available), were reviewed for inclusion in the article. The International Society for Pharmacoeconomics and Outcomes Research abstract database \[[@CR22]\] was also searched for inclusion of relevant studies published between 2014 and 2017. Data from the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project \[[@CR23]\] were used to determine annual hospitalizations for patients with HE, which were coded according to one of three *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) codes for HE: 291.2 (alcoholic dementia, not elsewhere classified), 348.30 (encephalopathy, not otherwise specified), and 572.2 (hepatic coma) \[[@CR23]\].

Inclusion {#Sec4}
---------

Publications selected for inclusion during formal review were those that reported on economic evaluations of patients with HE and patients with HE receiving rifaximin, lactulose, or rifaximin plus lactulose. Further, studies examining quality of life (QOL) in patients with HE and HE as an outcome in patients with cirrhosis were considered for inclusion in this review. Studies were excluded if patients included were aged \< 18 years, did not receive rifaximin and/or lactulose, or had minimal (or covert) HE. Narrative reviews were also excluded.

Assessment of Methodological Quality of Economic Studies {#Sec5}
--------------------------------------------------------

The 10-item Drummond checklist was used to evaluate the quality of methods reported for the economic studies identified for inclusion in this systematic review \[[@CR24]\]. Criteria for exclusion of economic studies were a combined lack of economic importance of the research question, failure to identify competing alternatives, and outcomes not relevant to the current review. No studies identified for inclusion in this review were excluded based on this quality assessment.

Results {#Sec6}
=======

Identification of Studies {#Sec7}
-------------------------

The search for economic studies related to HE that were published since 2007, as well as studies related to the use of lactulose and/or rifaximin for the management of HE, found 133 articles or abstracts, of which 16 were identified for inclusion in this systematic review because they contained cost data related to overt HE (Fig. [1](#Fig1){ref-type="fig"}). Specifically, nine articles (including two systematic reviews) were identified as being related to economic costs of overt HE, and seven articles or abstracts were considered related to costs associated with rifaximin and/or lactulose for patients with overt HE. Excluded from further review were review articles (excluding systematic reviews) and studies of paediatric patients or minimal or covert HE, as well as studies that included other HE treatments or did not include economic data.Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram detailing the search for records pertaining to economic data for hepatic encephalopathy, and administration of rifaximin and/or lactulose. Search terms included hepatic encephalopathy, economic, health-related quality of life, cost, cost utility, cost effectiveness, rifaximin, lactulose adherence, and patient-reported outcomes. *HE* hepatic encephalopathy

Economic Impact of Hepatic Encephalopathy {#Sec8}
-----------------------------------------

Data from the US Nationwide Inpatient Service indicate that the number of HE-related hospitalizations increased annually between 2004 and 2014, excepting 2008 (from 95,232 in 2004 to 156,205 in 2014) \[[@CR23]\]. Further, in 2014, for patients with a primary diagnosis of HE (ICD-9-CM diagnosis code 572.2; *n* = 55,485), unadjusted (for the medical consumer price index) total costs were estimated at approximately \$US620 million \[[@CR23]\]. These data from the US Nationwide Inpatient Service \[[@CR23]\], and data in published studies (Table [1](#Tab1){ref-type="table"}) \[[@CR21], [@CR25]--[@CR32]\], demonstrate the economic impact of HE-related hospitalizations.Table 1Economic costs associated with hepatic encephalopathyStudy; country; perspectivePopulationOutcome(s)Cost(s)Irish et al. \[[@CR32]\]; USA; payer perspectivePts with HE-related hospitalization in 2012; Medicare claims database (*n* = 1113)Mean no. of hospitalizations: 2.4\
Mean duration of hospitalization: 5.9 days\
Mean no. of outpatient visits: 11.0Mean hospitalization costs: \$US25,364--58,625Poovorawan et al. \[[@CR27]\]; Thailand; payer perspectivePts with cirrhosis (ICD-10 code K74)-related hospitalization in 2010 (*n* = 92,301 admissions)\
Pts with HE (*n* = 5292)Mean ± SD duration of HE-related hospitalization: 9.1 ± 10.9 days\
Mortality during hospitalization: 32%Mean ± SD hospitalization costs: THB44,606 ± 71,001; \$US1394 ± 2219\
Total healthcare costs: THB58,134 ± 79,763; \$US1817 ± 2493Roggeri et al. \[[@CR21]\]; Italy; payer perspectivePts with ≥ 1 overt HE-related hospitalization between 1 January 2011 and 31 December 2011 (*n* = 381)Mortality\
During index hospitalization (*n* = 82; 21.5%)\
During hospitalization at 1-year follow-up (*n* = 22; 5.8%)\
Mean ± SD duration of overt HE recurrence-related hospitalization: 9 ± 7 daysMean ± SD direct costs of single overt HE recurrence-related hospitalization^a^: €3361 ± 1286; \$US3838 ± 1469\
Total annual costs for pts with (*n* = 124) and without (*n* = 172) overt HE recurrence: €21,272 (\$US24,293) vs. €12,098 (\$US13,816), respectively (*p *\< 0.001)\
Mean ± SD annual hospitalization cost with recurrence vs. no recurrence: €18,970 ± 16,652 vs. €10,196 ± 22,182\
Mean ± SD annual drug cost with recurrence vs. no recurrence: €1633 ± 1807 vs. €1173 ± 1657\
Mean ± SD annual diagnostic and therapeutic procedure costs with recurrence vs. no recurrence: €669 ± 974 vs. €729 ± 1519Benković et al. \[[@CR28]\]; Croatia; payer perspectivePts with malnutrition and HE in 2012 (*n* = 945)Total healthcare costs: €1,019,994\
Mean healthcare costs/pt: €1344Lee et al. \[[@CR29]\]; China; payer perspectivePts with HE (ICD-9-CM diagnosis code 572.2) associated with benzodiazepine use enrolled in previous (2005--2009) and current (2009--2012) clinical studies at single hospital (*n* = 322)Mean ± SD HE-related healthcare costs\
Hospitalization: NTD6987 ± 419; \$US231 ± 14\
Outpatient visits: NTD812 ± 99; \$US27 ± 3\
ER visits: NTD4170 ± 641; \$US138 ± 21\
Overall medical costs: NTD11,970 ± 210; \$US396 ± 7Andersen et al. \[[@CR30]\]; Denmark; provider perspectivePts with cirrhosis with previous HE-related hospitalization receiving outpatient rehabilitation (2009; *n* = 19) vs. pts not receiving rehabilitation (i.e. control group; 2008; *n* = 14)Survival (≤ 20 months from baseline; rehabilitation group vs. control group): 84 vs. 36%, respectively; *p *= 0.01Median (range) costs\
Rehospitalization at study hospital\
Rehabilitation group: DKK52,266 (0--409,402); \$US9643 (0--75,535)\
Control group: DKK51,266 (0--410,128); \$US9459 (0--75,669)\
Rehospitalization at any hospital\
Rehabilitation group: DKK84,730 (0--409,402); \$US15,633 (0--75,535)\
Control group: DKK84,395 (0--471,562); \$US15,571 (0--87,004)El Khoury et al. \[[@CR26]\]; Brazil, Canada, Asia-pacific region, Europe (systematic review); payer (*n* = 3 studies) and provider (*n* = 7 studies) perspective; perspective unknown for 1 studyPts with HE related to HCV infection\
Studies published between January 1990 and January 2011 (*n* = 11 studies)Mean (range) global HE-related costs (2010 values): \$US13,270 (5370--50,120)El Khoury et al. \[[@CR25]\]; USA (systematic review); provider perspective (*n* = 5 studies)Pts with HE associated with HCV infection\
Studies published between 1997 and 2007 (*n* = 5)Mean HE-related costs (2010 values)\
Year 1: \$US16,430\
Year 2: \$US3810Stepanova et al. \[[@CR31]\]; USA; payer perspectivePts with HE-related hospitalizations between 2005 and 2009 (*n* = 111,090)Mean ± SD duration of HE-related hospitalization\
2005: 8 ± 0.2 days\
2009: 8.5 ± 0.2 days\
Mean no. procedures\
2005: 1.9 ± 0.1\
2009: 2.2 ± 0.1\
In-hospital mortality\
2005: 15.6%\
2009: 14.4%Total HE-related hospitalization charges\
2005: \$US4.677 billion\
2009: \$US7.254 billion\
Mean HE-related hospitalization charges\
2005: \$US 46,663 ± 2180\
2009: \$US63,107 ± 3244\
Mean HE-related costs per pt\
2005: \$US16,512 ± 709\
2009: \$US17,812 ± 764*DKK* Danish krone, *ER* emergency room, *HCV* hepatitis C virus, *HE* hepatic encephalopathy, *ICD-9-CM* International Classification of Diseases, Ninth Revision, Clinical Modification, *ICD-10* ICD, Tenth Revision, *mo* month, *NTD* New Taiwan dollars, *pt* patient, *SD* standard deviation, *THB* Thai baht^a^Exchange rate €1.00 = \$US1.1420

A systematic review of 11 economic costs studies for countries with available data (excluding the USA) published between 1990 and 2011 estimated mean annual HE-related costs at \$US13,270 per patient (range 5370--50,120); the methodologies for collecting cost data for each study included in the systematic review were highly variable \[[@CR26]\]. A systematic review of US studies of patients with hepatitis C-related sequelae estimated that annual HE-related costs were \$US16,430 in the first year and \$US3810 annually in subsequent years, although these values are likely an underestimate of current costs, given that many studies included in the systematic review relied on a small single-centre study from 1997 \[[@CR25]\]. The broad range of economic costs observed are consistent with the findings of this systematic review of seven independent studies examining economic costs associated with HE worldwide (Table [1](#Tab1){ref-type="table"}) \[[@CR21], [@CR27]--[@CR32]\]: we found a broad range of mean annual hospitalization costs (2012) for patients with HE, with between \$US25,634 and \$US58,625 reported for the USA \[[@CR32]\].

Management of Hepatic Encephalopathy and Clinical Impact {#Sec9}
--------------------------------------------------------

Management of overt HE includes treating patients with acute HE episodes, preventing HE recurrence, and identifying and managing precipitating factors associated with development of HE \[[@CR1]\]. First-line therapy for patients experiencing an acute episode of overt HE is the nonabsorbable disaccharide lactulose, which requires self-titration to two to three soft bowel movements per day \[[@CR1]\]. Rifaximin is an oral non-systemic antibiotic approved in the USA for reduction of risk of overt HE recurrence in adults; the recommended dosing is 550 mg twice daily. Guidelines from the AASLD and EASL recommend rifaximin as add-on therapy to lactulose to reduce the risk of overt HE recurrence \[[@CR1]\].

### Lactulose for Hepatic Encephalopathy {#Sec10}

A meta-analysis of 22 randomized controlled studies demonstrated that nonabsorbable disaccharides (i.e. lactulose, lactitol) were significantly more effective than placebo or no intervention for the prevention and treatment of HE (relative risk (RR) 0.58; 95% CI 0.48--0.69) \[[@CR33]\]. A meta-analysis of 24 randomized controlled studies demonstrated that nonabsorbable disaccharides significantly reduced the risk of mortality compared with placebo or no intervention (RR 0.59; 95% CI 0.40--0.87) \[[@CR33]\]. For hospitalized patients with end-stage liver disease, lactulose use was associated with decreased risk of *Clostridium difficile* infection (OR 0.48; 95% CI 0.31--0.74; *p *\< 0.001) \[[@CR34]\], which is important given that *C. difficile* infection is associated with poor outcomes in hospitalized patients with cirrhosis (i.e. higher mortality rate, longer hospital stay, increased hospital costs) \[[@CR35]\].

### Rifaximin for the Management of Hepatic Encephalopathy {#Sec11}

Rifaximin is indicated in the USA for reducing the risk of overt HE recurrence in adults but not for management of an acute episode of overt HE. However, in one study, a significantly greater percentage of patients receiving rifaximin plus lactulose experienced complete reversal of an acute overt HE episode compared with those receiving lactulose alone after 10 days (76.2 vs. 43.9%, respectively; *p *= 0.004) \[[@CR36]\]. Rifaximin plus lactulose was associated with decreased mortality compared with lactulose alone (23.8 vs. 49.1%; *p *\< 0.05) \[[@CR36]\]. In addition, rifaximin has demonstrated efficacy for reducing the risk of overt HE recurrence. In a Greek study, rifaximin decreased the risk of overt HE recurrence (*p *= 0.03) and improved survival (*p *= 0.01) in patients with alcohol-related decompensated cirrhosis compared with patients not receiving rifaximin during a 5-year period \[[@CR37]\]. In a US single-centre retrospective study, a significantly lower percentage of patients receiving rifaximin and lactulose combination therapy for acute HE were rehospitalized for HE-related reasons within 6 months compared with patients receiving lactulose alone (2.4 vs. 16.2%, respectively; *p *= 0.03) \[[@CR38]\]. In a 6-month phase III randomized, double-blind, placebo-controlled study in patients with a history of overt HE (*n* = 299), rifaximin reduced the risk of breakthrough HE by 58% (HR 0.42; 95% CI 0.28--0.64; *p *\< 0.001) compared with placebo; of note, 91% of patients in each group received concomitant lactulose \[[@CR39]\]. Twice-daily rifaximin improved sleep quality after 28 days in patients with a history of HE \[[@CR7]\]. Finally, a meta-analysis of 12 randomized controlled studies of patients with minimal or overt HE demonstrated that rifaximin significantly decreased the risk of mortality compared with lactulose/lactitol, other antibiotics, or placebo (RR 0.64; 95% CI 0.43--0.94) \[[@CR40]\].

A retrospective chart review of patients with overt HE demonstrated the durability of rifaximin for the maintenance of HE remission, as 81.2% of 149 patients receiving monotherapy (mean duration 255 days) and 66.7% of 54 patients receiving rifaximin and lactulose combination therapy (mean duration 205 days) did not experience HE recurrence during 1 year of follow-up \[[@CR41]\]. In that study, of the 28 (18.8%) patients receiving rifaximin monotherapy and the 18 (33.3%) receiving rifaximin with lactulose who experienced breakthrough HE, 42.9 and 38.9% required hospitalization for overt HE, respectively, and 14.3 and 27.8% required hospitalization for dehydration and overt HE, respectively \[[@CR41]\]. In another US single-centre study, rifaximin significantly reduced the odds of rehospitalization within 30 days in patients with overt HE (OR 0.39; 95% CI 0.16--0.87; *p *= 0.02) \[[@CR42]\]. Rifaximin was associated with a decrease in hospitalizations \[[@CR43]\]; in one study, 30-day and 6-month rehospitalization rates in patients with HE receiving rifaximin 550 mg twice daily were 9.4 and 15.6%, respectively \[[@CR44]\]. Patients with HE who were crossed over from placebo to receive open-label rifaximin in a randomized controlled trial had a numeric decrease in HE-related hospitalizations within 6 months, although significance was not achieved (0.36 vs. 0.57 events/person-years of exposure; *p *= 0.4) \[[@CR43]\]. In a phase III randomized controlled trial of patients with a history of overt HE (*n* = 299), rifaximin 550 mg twice daily reduced the risk of HE-related hospitalization by 50% compared with placebo during a 6-month period (HR 0.50; 95% CI 0.29--0.87; *p *= 0.01); overall, 13.6 and 22.6% of patients, respectively, experienced HE-related hospitalizations \[[@CR39]\]. In a long-term open-label study, rifaximin was associated with decreased rates of overt HE- and all-cause-related hospitalizations for ≥ 2 years compared with patients receiving placebo for ≥ 6 months (historical comparison group) \[[@CR45]\]. A single-centre retrospective study reported that patients with more severe liver disease (i.e. Model for End-Stage Liver Disease (MELD) score \> 20; *n* = 43) receiving rifaximin plus lactulose for ≥ 6 months had a lower mean number of HE-related hospitalizations than did patients with a MELD score \< 20 (*n* = 49; 1.6 vs. 2.5 hospitalizations, respectively) \[[@CR46]\]. However, retrospective analysis of a US pharmacy claims database (1 January 2006 through 30 June 2015) found no difference in overt HE-related hospitalizations between rifaximin plus lactulose vs. lactulose monotherapy (16.0 vs. 15.3%, respectively; *p *= 0.8) \[[@CR47]\]. Furthermore, there was no significant reduction in the risk of an overt HE episode between the two groups (HR 1.04; 95% CI 0.81--1.28) \[[@CR47]\]. These findings are currently limited to presentation in abstract form, and it is unclear why these data differ from the positive data noted above. The abstract authors speculated that this difference may be related to unobserved confounding \[[@CR47]\]. Overall, data support that rifaximin is effective for reducing all-cause- and HE-related hospitalizations in patients with a history of overt HE.

Impact of Therapy on Hepatic Encephalopathy Costs and Outcomes {#Sec12}
--------------------------------------------------------------

Rifaximin and lactulose combination therapy has been shown to significantly decrease the duration of hospital stays vs. lactulose alone (5.8 ± 3.4 vs. 8.2 ± 4.6 days; *p *= 0.001) \[[@CR36]\], even given the higher monthly drug cost of rifaximin vs. lactulose \[[@CR48], [@CR49]\]. Congly and Leise \[[@CR48]\] suggested a favourable economic impact of rifaximin on hospitalizations. Lactulose was associated with significantly worse adherence (i.e. taking ≥ 75% of doses as prescribed by patient self-report) compared with rifaximin in a single-centre retrospective study of patients with HE receiving lactulose twice daily for ≥ 6 months, followed by rifaximin alone three times daily for ≥ 6 months (31 vs. 92%, respectively; *p *\< 0.001) \[[@CR50]\]. In that study, during the ≥ 6-month timeframe, lactulose was associated with a greater number of hospitalizations than was rifaximin alone (1.6 vs. 0.5, respectively; *p *\< 0.001) as well as longer duration of hospitalization (7.3 vs. 2.5 days; *p *\< 0.001) and higher hospitalization costs per patient (\$US56,635 vs. 14,222; year 2005 values; payer perspective) \[[@CR50]\]. Data from a single-centre retrospective study of patients receiving lactulose monotherapy found that dehydration and failure to adhere to therapy were predictors of HE recurrence \[[@CR51]\]. A US single-centre retrospective study of patients hospitalized for HE indicated that lactulose use after initial hospitalization was a significant factor associated with rehospitalization within 90 days (OR 8.6; 95% CI 1.1--66.7; *p *= 0.03); however, rifaximin use posthospitalization was not significantly associated with risk of rehospitalization within 90 days (OR 1.2; 95% CI 0.7--2.2; *p* = 0.3) \[[@CR52]\].

The adverse effects associated with lactulose, including diarrhoea, abdominal pain, and bloating, were associated with nonadherence to lactulose and resulted in a failure to adequately titrate lactulose to the appropriate number of daily bowel movements \[[@CR51]\]; in one study, failure to properly titrate lactulose was a common cause of preventable rehospitalization in patients with HE who were readmitted within 1 month of their last hospital stay \[[@CR53]\]. A significantly greater percentage of patients experienced diarrhoea, flatulence, and abdominal pain with lactulose compared with rifaximin alone (*p *\< 0.001, for each comparison) \[[@CR50]\]. Further, a meta-analysis of eight controlled clinical studies demonstrated that rifaximin had a more favourable safety profile than lactulose, as the risks of diarrhoea and abdominal pain were significantly less with rifaximin than with lactulose (diarrhoea RR 0.11; 95% CI 0.04--0.31; *p *\< 0.0001; abdominal pain RR 0.34; 95% CI 0.14--0.83; *p *= 0.02; both adverse events together RR 0.19; 95% CI 0.10--0.37; *p *\< 0.00001) \[[@CR54]\]. Nonadherence to lactulose, in part related to adverse events, appeared to play a role in HE recurrence and HE-related rehospitalization, both events that are associated with economic costs that may be avoidable in some patients.

In the UK, healthcare resource utilization was significantly decreased after initiation of rifaximin compared with before initiation of rifaximin (Table [2](#Tab2){ref-type="table"}) \[[@CR55], [@CR56]\]. In one study, use of rifaximin (with 87% of patients receiving concomitant lactulose) to reduce the risk of overt HE decreased mean annual inpatient admission costs compared with the year prior to rifaximin (₤12,522 per year before rifaximin vs. ₤5915 per year after rifaximin; provider perspective) \[[@CR55]\] (Table [3](#Tab3){ref-type="table"}) \[[@CR55], [@CR57]--[@CR62]\]. When considering the annual cost of rifaximin at the time of the study (₤3379), the mean annual cost savings per patient were ₤3228 \[[@CR55]\].Table 2Effects of rifaximin on healthcare resource utilization \[[@CR55], [@CR56]\]Study; countryCentre (pts), *n*Data collectionOutcomes (prior to rifaximin vs. with rifaximin^a^)Month 3Month 6Month 12Orr et al. 2016 \[[@CR55]\], UK7 (326)2014Mean all-cause hospitalizations^b^: 1.2 vs. 0.6 (*p *\< 0.001)\
Mean hospital LOS (d)^b^:\
15.8 vs. 7.4 (*p *\< 0.001)Mean all-cause hospitalizations^b^: 1.6 vs. 1.0 (*p *\< 0.001)\
Mean hospital LOS (d)^b^:\
20.7 vs. 9.7 (*p *\< 0.001)Mean all-cause hospitalizations^b^: 2.1 vs. 1.6 (*p *= 0.001)\
Mean hospital LOS (d)^b^: 24.4 vs. 11.5 (*p *\< 0.001)Aspinall et al. 2016 \[[@CR56]\], UK11 (145)July 2008--May 2014Not reportedMean hospitalizations: 2.2 vs. 1.0 (*p *\< 0.001)\
Total inpatient bed days: 28.6 vs. 11.9 (*p *\< 0.001)\
Critical care bed days/pt: 7.9 vs. 2.0 (*p *= 0.046)\
ER visits/pt: 1.9 vs. 1.0 (*p *\< 0.001)Mean hospitalizations: 2.7 vs. 1.7 (*p *= 0.002)\
Total inpatient bed days: 31.7 vs. 16.4 (*p *\< 0.001)\
Critical care bed days/pt: 11.3 vs. 2.4 (*p *= 0.017)\
ER visits/pt: 2.4 vs. 1.8 (*p *= 0.099)*d* day, *ER* emergency room, *LOS* length of stay, *pt* patient^a^Time points for outcomes assessed after rifaximin was initiated^b^*n* = 158 Table 3Pharmacoeconomic profile of rifaximinCountryPatient characteristicsEndpoint(s) and modelOutcomesBelgium \[[@CR61]\]Recurrent overt HEICER, derived from QALY\
Markov state transition modelLactulose (SOC)\
 Average cost (2010): €44,190\
 1.9 QALY/pt\
 Average cost effectiveness: €23,258/QALY\
Rifaximin + lactulose\
 Average cost: €31,262\
 2.5 QALY/pt\
 Average cost effectiveness: €12,505/QALY\
ICER: €21,547/QALY for rifaximin + lactulose vs. lactuloseFrance \[[@CR57]\]History of overt HE (≥ 2 episodes); currently in remissionICER, derived from QALY\
Markov state transition modelLactulose (SOC)\
 2 years\
  Cost: €5503\
  0.967 QALY/pt\
 5 years\
  Cost: €8555\
  1.778 QALY/pt\
Rifaximin + lactulose\
 2 years\
  Cost: €7639\
  1.078 LY/pt\
 5 years\
  Cost: €14,411\
  2.094 QALY\
ICER\
 2 years: €19,187/QALY for rifaximin + lactulose vs. lactulose\
 5 years: €18,517/QALY for rifaximin + lactulose vs. lactuloseNetherlands \[[@CR59]\]Recurrent overt HEICER, derived from QALY\
Markov state transition modelLactulose (SOC)\
 Average cost (2010): €82,968\
 1.89 QALY/pt\
Rifaximin + lactulose\
 Average cost: €88,386\
 2.45 QALY/pt\
ICER (5 years): €9576/QALY for rifaximin + lactulose vs. lactuloseSweden \[[@CR60]\]Recurrent overt HEICER, derived from QALY\
Markov state transition modelLactulose (SOC)\
 Average cost (2012): €42,522\
 1.83 QALY/pt\
Rifaximin + lactulose\
 Average cost: €32,667\
 2.38 QALY/pt\
ICER (5 years): €17,918/QALY for rifaximin + lactulose vs. lactuloseUK \[[@CR55]\]Overt HE^a^Cost analysis of rifaximinMean annual emergency inpatient admission costs, 1 year before vs. 1 year after rifaximin: ₤12,522 vs. ₤5915, respectively (2013/2014 costs)UK \[[@CR58]\]Recurrent overt HEICER, derived from QALY\
Markov state transition modelLactulose (SOC)\
 Average cost (2012): ₤23,545\
 1.83 QALY/pt\
Rifaximin\
 Average cost: ₤22,971\
 2.36 QALY/pt\
ICER\
 5 years: ₤1083/QALY for rifaximin vs. lactulose\
 10 years: ₤4470/QALY for rifaximin vs. lactulose\
 Lifetime: ₤7215/QALY for rifaximin vs. lactuloseUSA \[[@CR62]\]Recurrent overt HECosts (drug costs, hospitalizations, liver transplant)\
Outcomes (hospitalizations, LY, QALY)Rifaximin + lactulose vs. lactulose\
 Life expectancy improved with rifaximin + lactulose vs. lactulose (lifetime, 5.7 vs. 2.8 years)\
 Opportunity for liver transplant improved 2-fold with rifaximin + lactulose vs. lactulose\
 Hospitalizations were decreased with rifaximin + lactulose vs. lactulose over 6 mo (0.27/pt vs. 0.51/pt)\
Lifetime cost of rifaximin: \$US 59,777\
\$US 20,287/LY for rifaximin + lactulose vs. lactulose\
\$US 26,672/QALY for rifaximin + lactulose vs. lactulose*HE* hepatic encephalopathy, *ICER* incremental cost-effectiveness ratio, *LY* life-years, *QALY* quality-adjusted life years, *SOC* standard of care^a^In this study, costs were compared before and after initiation of rifaximin

In France, rifaximin plus lactulose had a favourable pharmacoeconomic profile compared with lactulose monotherapy, based on a societal willingness-to-pay cost-effectiveness threshold of €27,000 (Table [3](#Tab3){ref-type="table"}); the incremental cost-effectiveness ratio of rifaximin to lactulose was €18,517 per each quality-adjusted life-year gained over 5 years, suggesting that rifaximin in combination with lactulose was a cost-effective treatment for patients with a history of at least two HE episodes \[[@CR57]\]. In the USA and other countries, clinically relevant benefits of rifaximin (e.g. reduction in hospitalizations, decreased mortality rate, reversal of HE symptoms, maintenance of remission of HE) have been demonstrated in pharmacoeconomic studies (Table [3](#Tab3){ref-type="table"}) \[[@CR55], [@CR57]--[@CR62]\]. Finally, applying the 50% reduction in HE-related hospitalizations attributable to rifaximin by Bass et al. \[[@CR39]\] to the 22,931 HE-related hospitalizations at \$US63,107 annual inpatient charges per episode reported by Stepanova et al. \[[@CR31]\] reveals a potential inpatient cost avoidance for the payer of \> \$US723 million annually in the USA (2009 values). However, this cost avoidance potential must be considered within the context of charges as a valuation vs. actual costs, any additional costs of therapy, potential cost savings for other direct medical costs and indirect costs, the potential increases in both the incidence and the cost of HE-related hospitalizations since 2009, and the number of patients treated.

Discussion {#Sec13}
==========

In this systematic review, the global economic costs associated with HE-related healthcare utilization are summarized for the past 10 years. Patients with HE, regardless of geographic location, present a substantial economic burden on the healthcare infrastructure, and annual hospitalizations for patients with HE can be quite costly to the healthcare system. Mean duration of hospital stay related to HE ranged between 5.9 \[[@CR32]\] and 9 days \[[@CR21], [@CR27]\] in the literature, with a mean of 2.4 yearly hospitalizations for patients with HE \[[@CR32]\]. A study of patients previously hospitalized for liver disease showed a mean 1.5 HE-related readmissions annually \[[@CR13]\]. Overall, data suggest that initiating rifaximin therapy early in the hospital setting could lead to decreased length of stay \[[@CR55]\]. Furthermore, the cost savings estimated for rifaximin vs. lactulose, while based on published estimates of numbers affected, support the idea that reducing the risk of hospitalization in patients with HE would significantly reduce the economic burden to healthcare systems for this condition. Indeed, the incremental costs of rifaximin are outweighed by the potential savings in healthcare costs.

Irish et al. \[[@CR32]\] demonstrated that patients with HE enrolled in a government-sponsored healthcare programme had an average of 11 outpatient visits annually. The literature suggests that rifaximin may provide better control of HE symptoms and, in turn, may reduce not only hospitalization-related costs and duration of hospital stay but also other healthcare-related costs, especially if rifaximin use translates into reduced need for ambulatory follow-up \[[@CR39], [@CR45]\]. However, more research is needed to confirm and quantify the extent to which rifaximin use may reduce healthcare-related costs.

Rifaximin with or without lactulose is associated with improvement in both the number and the duration of hospitalizations in patients with HE \[[@CR55], [@CR56]\]. Further, studies conducted in different countries demonstrated that rifaximin combined with lactulose had a more favourable cost-effectiveness profile than lactulose alone \[[@CR55], [@CR57]--[@CR62]\]. It should be noted that the data presented in some of these studies are in the form of meeting abstracts \[[@CR32], [@CR56], [@CR58]--[@CR62]\], thus limiting the details presented regarding study design and outcomes (Table [4](#Tab4){ref-type="table"}) \[[@CR21], [@CR25]--[@CR32], [@CR55]--[@CR62]\].Table 4Quality assessment of economic studies^a^StudyWell-defined questionComprehensive description of competing alternativesEvidence of programme's effectivenessImportant and relevant outcomes for each alternative identifiedOutcomes and costs measured accurately in appropriate unitsOutcomes and costs valued crediblyOutcomes and costs adjusted (e.g. discounting)Incremental analysis of outcomes and costs of alternatives performedSensitivity analysis performedConclusions justified by the evidenceAndersen et al. 2013^b^ \[[@CR30]\]NoYesYesYesYesNot clearNoNoNoYesBenković et al. 2014^b^ \[[@CR28]\]YesYesYesYesYesYesNoNoNoYesBerni et al. 2015^c^ \[[@CR61]\]YesYesYesYesYesYesYesYesNot clearYesBerni et al. 2015^c^ \[[@CR58]\]YesYesYesYesYesYesYesYesYesYesBozkaya et al. 2014^b^ \[[@CR62]\]YesYesYesYesYesYesNot clearYesNot clearYesEl Khoury et al. 2012^d^ \[[@CR26]\]YesYesYesYesYesYesYesNoNoYesEl Khoury et al. 2012^d^ \[[@CR25]\]YesYesYesYesYesYesYesNoNoYesIrish et al. 2015^c^ \[[@CR32]\]YesYesYesYesYesNot clearNot clearNot clearNoYesKabeshova et al. 2015^b^ \[[@CR57]\]YesYesYesYesYesYesYesYesYesYesLee et al. 2014^b^ \[[@CR29]\]YesYesYesYesYesYesNoNoNoYesOrr et al. 2016^b^ \[[@CR55]\]YesYesYesYesYesYesNoNoNoYesPoole et al. 2015^c^ \[[@CR60]\]YesYesYesYesYesYesYesYesYesYesPoovorawan et al. 2015^b^ \[[@CR27]\]YesYesYesYesYesYesNoNoNoYesRoggeri et al. 2015^b^ \[[@CR21]\]YesYesYesYesYesYesNoNoNoYesStepanova et al. 2012^b^ \[[@CR31]\]YesYesYesYesYesYesYesNoNot clearYesWhitehouse et al. 2015^c^ \[[@CR59]\]YesYesYesYesYesYesYesYesNot clearYes^a^Possible responses are yes, no, and not clear^b^Published article^c^Abstract^d^Systematic review

A limitation of the current systematic review is that available data originate from multiple countries and often involve different timeframes. Variances in healthcare systems worldwide may limit the generalizability of the economic findings to a single country. Guidelines from the AASLD and EASL recommend lactulose as first-line therapy and rifaximin as add-on therapy for reducing the risk of recurrence of overt HE \[[@CR1]\]. Another limitation of the current review is the paucity of economic data published for management of overt HE. This review included any publications meeting inclusion criteria since 2007; thus, two systematic reviews of costs in the USA and the rest of the world were included \[[@CR25], [@CR26]\]. Further, as shown in Table [4](#Tab4){ref-type="table"}, most of the cost data presented in the current systematic review did not undergo adjustment (e.g. to medical consumer price index), restricting head-to-head comparisons. Finally, while the pharmacoeconomic benefits of rifaximin appear to be favourable, a more thorough analysis is warranted to provide a current estimate of savings to the US healthcare system. Any such study utilizing more current estimates of the number of patients with cirrhosis and HE should employ sensitivity analyses representing higher prevalence estimates, given that the prevalence of cirrhosis and overt HE is likely underestimated \[[@CR63]\] for several reasons, including nonspecific ICD-10 diagnosis coding.

Conclusions {#Sec14}
===========

Rifaximin, either alone or in combination with lactulose, improved outcomes in patients with HE compared with lactulose alone. Rifaximin (with or without lactulose) decreased healthcare resource utilization in patients with overt HE and was associated with a favourable pharmacoeconomic profile compared with lactulose alone. Economic data are favourable for use of rifaximin (with or without lactulose) for reducing the risk of overt HE recurrence in patients with a history of overt HE. Therefore, reducing the risk of recurrence of overt HE (e.g. with rifaximin) to reduce hospital readmission should be a consideration at discharge for adults with cirrhosis who were hospitalized due to overt HE.

The original version of this article was revised due to a retrospective Open Access Order.

A correction to this article is available online at <https://doi.org/10.1007/s40273-018-0676-8>.
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